GlassScriptPhysician profile
Jay I Peters
NPI 1306856711
$2,979.24
in general payments reported to CMS, 2019-2025
19 companies · $442 in 2025
The $442 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $183 · 2021: $17.24 · 2022: $12.51 · 2023: $346 · 2024: $1,857 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $1,144.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,535.57 | 2019-2024 | |
| Amgen INC. | $337.89 | 2023-2025 | Tezspire, Tavneos |
| Mylan Specialty L.P. | $132.90 | 2020-2023 | Yupelri |
| Abbvie INC. | $125.41 | 2023-2025 | |
| La Jolla Pharmaceutical Company | $114.59 | 2024-2025 | Giapreza |
| Insmed, INC. | $113.66 | 2023-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $108.57 | 2020-2025 | Zerbaxa |
| Pulmonx Corporation | $108.50 | 2023-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Gilead Sciences, INC. | $58.71 | 2019-2024 | Veklury |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.47 | 2024 | Ofev |
| Shionogi INC | $52.15 | 2023 | Fetroja |
| Portola Pharmaceuticals, LLC | $48.10 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $45.87 | 2019-2020 | |
| United Therapeutics Corporation | $32.77 | 2024 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $30.58 | 2023 | Bevespi Aerosphere |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcresta Therapeutics, INC. | $28.61 | 2025 | Relizorb |
| Genzyme Corporation | $17.24 | 2021 | |
| Genentech USA, INC. | $15.64 | 2019 | |
| Chiesi USA, INC. | $15.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.